StocksMedium•14 October 2026•
1 min read
Arrowhead Pharmaceuticals Reports Positive Clinical Data for Alzheimer's Treatment
Key Facts
1Arrowhead Pharmaceuticals announced positive interim Phase 1/2a results for ARO-MAPT, an investigational treatment for Alzheimer's disease.
2The results represent the first successful clinical validation of a platform to deliver siRNA across the blood-brain barrier.
Arrowhead Pharmaceuticals announced positive interim Phase 1/2a results for ARO-MAPT, an investigational treatment for Alzheimer's disease. According to a statement from Business Wire, the results represent the first successful clinical validation of a platform to deliver siRNA across the blood-brain barrier.
ARWR closed at $58.13 on October 13, 2026, with the stock trading between a low of $58.08 and a high of $60.73 during that session. These clinical developments are part of the company's efforts to reduce target gene expression in the brain to treat neurological conditions.